注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Merrimack Pharmaceuticals Inc是一家生物制药公司。该公司有权收取与将Ipsen S.A.出售给ONIVYDE相关的或有付款,以及与将Elevation Oncology, Inc出售给MM-121和MM-111相关的或有付款。在ONIVYDE获得美国食品和药物管理局(FDA)批准后,Ipsen将支付ONIVYDE的某些额外临床适应症的费用。ONIVYDE被FDA批准与氟尿嘧啶(5-FU)和亚叶酸(LV)联合用于治疗以吉西他滨为基础的治疗后疾病进展后的胰腺转移性腺癌患者。该公司没有任何正在进行的研究或开发活动,正在为其剩余的临床前和临床资产寻找潜在的收购方。该公司的全资子公司包括Merrimack Pharmaceuticals UK Limited和Merrimack Securities Corporation。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Peter K. Sorger | 61 | - | Chairman of Scientific Advisory Board |
Gary L. Crocker | 70 | 2004 | President, Treasurer, Principal Financial Officer, Principal Accounting Officer, CEO & Chairman |
Eric David Andersen | 44 | 2019 | Independent Director |
Douglas A. Lauffenburger | - | - | Member of Scientific Advisory Board |
Josep Tabernero | - | 2018 | Member of Scientific Advisory Board |
Lee N. Newcomer | 69 | 2018 | Member of Scientific Advisory Board |
George Daniel Demetri | 65 | 2017 | Member of Scientific Advisory Board |
Peter Blume-Jensen | - | 2018 | Member of Scientific Advisory Board |
Ana Radeljevic | 42 | 2022 | Independent Director |
Noah Gabriel Levy | 45 | 2019 | Independent Director |
Ulrik B. Nielsen | 51 | 2009 | Co-Founder & Independent Director |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核